Evaluation of the Inhibitory Effect of Dihydropyridines on N-type Calcium Channel by Virtual Three-dimensional Pharmacophore Modeling

Abstract

Currently, a new type of calcium channel blockers, which can inhibit not only L-type calcium channels abundantly expressed in vascular smooth muscles, but also N-type calcium channels that abound in the sympathetic nerve endings, have been developed. In this study, analysis on a like-for-like basis of the L- and N-type calcium channel-inhibitory activity of typical dihydropyridine-type calcium-channel blockers (DHPs) was performed. Moreover, to understand the differences of N-type calcium channel inhibition among DHPs, the binding of DHPs to the channel was investigated by means of hypothetical three-dimensional pharmacophore modeling using multiple calculated low-energy conformers of the DHPs. All of the tested compounds, i. e. cilnidipine (CAS 132203-70-4), efonidipine (CAS 111011-76-8), amlodipine (CAS 111470-99-6), benidipine (CAS 85387-35-5), azelnidipine (CAS 123524-52-7) and nifedipine (CAS 21829-25-4), potently inhibited the L-type calcium channel, whereas only cilnidipine inhibited the N-type calcium channel (IC₅₀ value: 51.2 nM). A virtual three-dimensional structure of the N-type calcium channel was generated by using the structure of the peptide ω-conotoxin GVIA, a standard inhibitor of the channel, and cilnidipine was found to fit well into this pharmacophore model. Lipophilic potential maps of ω-conotoxin GVIA and cilnidipine supported this finding. Conformational overlay of cilnidipine and the other DHPs indicated that amlodipine and nifedipine were not compatible with the pharmacophore model because they did not contain an aromatic ring that was functionally equivalent to Tyr13 of ω-conotoxin GVIA. Azelnidipine, benidipine, and efonidipine, which have this type of aromatic ring, were not positively identified due to intrusions into the excluded volume. Estimation of virtual three-dimensional structures of proteins, such as ion channels, by using standard substrates and/or inhibitors may be a useful method to explore the mechanisms of pharmacological and toxicological effects of substrates and/or inhibitors, and to discover new drugs.

Key words

Amlodipine - Azelnidipine - Benidipine - Calcium channel blockers, dihydropyridine, L-type, N-type - Cilnidipine - Efonidipine - Nifedipine - Pharmacophore modeling

• Reference

• 1 Levy JH. Management of systemic and pulmonary hypertension. Tex Heart Inst J. 2005; 32: 467-71
• 2 Mason RP. Atheroprotective effects of long-acting dihydro-pyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research. Cerebrovasc Dis. 2003; 16 (Suppl. 3) 11-7
• 3 Sher E, Giovannini F, Codignola A, Passafaro M, Giorgi-Rossi P, Volsen S et al Voltage-operated calcium channel heterogeneity in pancreatic beta cells: physiopathological implications. J Bioenerg Biomembr. 2003; 35: 687-96
• 4 Kameyama A, Kameyama M. [Structure, function and expression of Ca²⁺ channels]. Nippon Rinsho. 1996; 54: 672-8
• 5 Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca²⁺ channel subtypes and pharmacology in the kidney. Circ Res. 2007; 16: 342-53
• 6 Watanabe K, Hosono M, Hayashi Y. Antihypertensive effect of Clinidipine (FRC-8653) in Stroke-Prone Spontaneously Hypertensive rats. Jpn Pharmacol Ther. 1995; 23: 3001-11
• 7 Yamanaka K, Suzuki M, Munehasu S, Ishiko J. [Effect of amlodipine][a new calcium antagonist on isolated blood vessels]. Nippon Yakurigaku Zasshi. 1991; 97: 167-78
• 8 Sata T, Mizuno M, Miyama C, Wada Y, Koike H. Pharmacological properties of azelnidipine, a long-acting calcium channel blocker with high-affinity for vascular tissues (Partl)-Calcium channel blocking actions in receptor binding and isolated blood vessel studies. Jpn Pharmacol Ther. 2002; 30: 703-9
• 9 Karasawa A, Kubo K. Calcium antagonistic effects and the in vitro duration of actions of KW-3049, a new 1,4-dihydro-pyridine derivative, in isolated canine coronary arteries. Jpn J Pharmacol. 1988; 47: 35-44
• 10 Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977; 17: 149-66
• 11 Masuda Y, Iwama T, Yamashita T, Sakai T, Hibi M, Tanaka S et al Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro. Arch Int Pharmacodyn Ther. 1991; 314: 57-73
• 12 Fujii S, Kameyama K, Hosono M, Hayashi Y, Kitamura K. Effect of cilnidipine, a novel dihydropyridine Ca⁺⁺-channel antagonist, on N-type Ca⁺⁺ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 1997; 280: 1184-91
• 13 Unayama H, Maeda K, Domoto H, Yoshimoto R, Inoue K, Akaike N. Cilnidipine blocks N-type Ca²⁺ channel in acutely dissociated rat sympathetic neurons. Jap J Pharmacol. 1997; 73: 267
• 14 Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T. Selectivities of dihydropyridine derivatives in blocking Ca²⁺ channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999; 291: 464-73
• 15 Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T. Comparison of binding affinities of ω-conotoxin and amlodipine to N-type Ca²⁺ channels in rat brain. Acta Pharmacol Sin. 1998; 19: 97-100
• 16 Ehlert FJ, Roeske WR, Itoga E, Yamamura HI. The binding of [³H] nitrendipine to receptors for calcium channel antagonists in the heart, cerebral cortex, and ileum of rats. Life Sci. 1982; 30: 2191-202
• 17 Gould RJ, Murphy KM, Snyder SH. [³H]nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists. Proc Natl Acad Sci USA. 1982; 79: 3656-60
• 18 Moresco RM, Govoni S, Battaini F, Trivulzio S, Trabucchi M. Omegaconotoxin binding decreases in aged rat brain. Neurobiol Aging. 1990; 11: 433-6
• 19 Sato K, Park NG, Kohno T, Maeda T, Kim JI, Kato R, Takahashi M. Role of basic residues for the binding of omegaconotoxin GVIA to N-type calcium channels. Biochem Biophys Res Commun. 1993; 194: 1292-6
• 20 Kim JI, Takahashi M, Ogura A, Kohno T, Kudo Y, Sato K. Hydroxyl group of Tyr13 is essential for the activity of omega-conotoxin GVIA, a peptide toxin for N-type calcium channel. J Biol Chem. 1994; 269: 23876-8
• 21 Flinn JP, Pallaghy PK, Lew MJ, Murphy R, Angus JA, Norton RS. Roles of key functional groups in omega-conotoxin GVIA synthesis, structure and functional assay of selected peptide analogues. Eur J Biochem. 1999; 262: 447-55
• 22 Miri R, Javidnia K, Sarkarzadeh H, Hemmateenejad B. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-l,4-dihydropyridines as calcium channel antagonist. Bioorg Med Chem. 2006; 15: 4842-9
• 23 Schleifer KJ. Stereoselective characterization of the 1,4-dihydropyridine binding site at L-type calcium channels in the resting state and the opened/inactivated state. J Med Chem. 1999; 42: 2204-11
• 24 Yao X, Liu H, Zhang R, Liu M, Hu Z, Panaye A et al QSAR and classification study of 1,4-dihydropyridine calcium channel antagonists based on least squares support vector machines. Mol Pharm. 2005; 2: 348-56
• 25 Valentijn K, Tranchand Bunel D, Vaudry H. Omega-conotoxin- and nifedipine-insensitive voltage-operated calcium channels mediate K⁺-induced release of prothyrotropin-releasing hormone-connecting peptides Ps4 and Ps5 from perifused rat hypothalamic slices. Brain Res Mol Brain Res. 1992; 14: 221-30
• 26 Favreau P, Gilles N, Lamthanh H, Bournaud R, Shimahara T, Bouet F et al A new omega-conotoxin that targets N-type voltage-sensitive calcium channels with unusual specificity. Biochemistry. 2001; 40: 14567-75
• 27 Villoutreix BO, Renault N, Lagorce D, Sperandio O, Montes M, Miteva MA. Free resources to assist structure-based virtual ligand screening experiments. Curr Protein Pept Sci. 2007; 8: 381-411
• 28 Li H, Yap CW, Ung CY, Xue Y, Li ZR, Han LY et al Machine learning approaches for predicting compounds that interact with therapeutic and ADMET related proteins. J Pharm Sci. 2007; 96: 2838-60